" class="no-js "lang="en-US"> Douglas Fambrough - Medtech Alert
Friday, May 23, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Douglas Fambrough

Douglas Fambrough

About Douglas Fambrough

Dicerna Pharmaceuticals is a publicly-traded (Nasdaq: DRNA) biotechnology company focused on the discovery and development of RNAi-based therapeutics in diverse therapeutic areas.

Related Story

Industry News

 Novo Nordisk to Acquire Dicerna Pharmaceuticals Including the RNAi Research Technology Platform | Pharmtech Focus

Novo Nordisk to Acquire Dicerna Pharmaceuticals Including the RNAi Research Technology Platform

November 18 2021

Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna […]